NCT04792502View on ClinicalTrials.gov

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2027

Conditions
Follicular LymphomaMarginal Zone LymphomaB-cell Lymphoma
Interventions
DRUG

Mosunetuzumab

Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.

DRUG

Lenalidomide

Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.

Trial Locations (3)

06511

NOT_YET_RECRUITING

Yale Cancer Center, New Haven

08901

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

02903

RECRUITING

Lifespan Cancer Insitute, Providence

Sponsors

Lead Sponsor

Brown University

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Brown University

OTHER

NCT04792502 - Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | Biotech Hunter | Biotech Hunter